Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Immune reconstitution after venetoclax-based treatments in CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBenjamin Heyman

Discussion

Loading...

Member takes

Overview

Analysis shows improvement in immune reconstitution in patients with CLL following venetoclax treatments, highlighting the impact on immunoglobulin levels.

Key Points

  • Overall, immune reconstitution demonstrated significant improvement in patients with chronic lymphocytic leukemia after venetoclax treatment.
  • Median IgA levels decreased from 38 mg/dL pre-treatment to 24.5 mg/dL post-treatment, then increased significantly by month 36.
  • A retrospective analysis of patients treated with venetoclax at a single center evaluated immunoglobulin recovery patterns.
  • Findings support the notion that venetoclax-based treatments could lead to humoral immune reconstitution, encouraging further research.

Cite This Study

Benjamin Heyman (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfddhttps://doi.org/10.1182/blood-2025-7403
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia2025
  2. 2Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial2025
  3. 3Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025
  4. 4Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  5. 5Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025